Aakha was founded by Hemanta Baruah in 2022.

Who are Aakha's investors?

Aakha's investors include 82VS.

How much funding has Aakha raised?

Aakha has disclosed $750K raised across 1 round.

Where is Aakha headquartered?

Aakha is headquartered in Frisco, US.

Aakha

Frisco, US · Founded 2022 · Delaware corporation · 8 employees on LinkedIn · 1 known investors

Find your way into Aakha

Paths you didn't know you had: your email and LinkedIn already hold routes to the Aakha team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.

Biotech Healthtech Medical Devices

Founders & leadership

Aakha was founded in 2022 by Hemanta Baruah.

Hemanta Baruah Founder & CEOHemanta Baruah has 15+ years of experience in antibody discovery, optimization, and protein engineering in industry and academic settings. He was a lead inventor of Sintilimab, an approved anti-PD-1 antibody, and previously directed multiple antibody discovery programs for various disease areas that advanced to clinical trials.

Board

Errik Anderson Board MemberBoard Director at Basecamp Fund

Christopher PachecoBoard director

George Robert Mabry IIIBoard director

Investors · 1

82VSlisted by 82VSBoston

How we know: 82VS's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$750K disclosed across 1 round · 2024

▶$750KraisedJul 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Christopher PachecoDirector
Hemanta BaruahExecutive Officer, Director
Errik AndersonDirector
George Robert Mabry IIIDirector

Offering amount: $5M
Amount sold: $750K
Proceeds to insiders: $100K
First sale: Jul 2024
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Apogee TherapeuticsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.

BeacontxBeacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

Companies working in the same space as Aakha.

Frequently asked questions

What does Aakha do?: Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
Who founded Aakha?: Aakha was founded by Hemanta Baruah in 2022.
Who are Aakha's investors?: Aakha's investors include 82VS.
How much funding has Aakha raised?: Aakha has disclosed $750K raised across 1 round.
Where is Aakha headquartered?: Aakha is headquartered in Frisco, US.